

Date	:	02/Oct/2016
Publication	:	Business Standard
Edition	:	Bengaluru
Media Type	:	News paper

Biocon: Scope for long-term gains

There is little doubt about the strength of the company's biosimilar portfolio but upsides are a couple of years away

By Anand Kumar

The Biocon stock has come through a roller coaster ride in the past year, with a fall of 11 per cent following the announcement of the company's Q1 FY16 results. The stock has since recovered to its previous levels, but the market is still watching the company's performance closely. The company's stock price has been volatile, with a high of ₹1,100 in early 2015 and a low of ₹750 in late 2015. The company's stock price has since recovered to its previous levels, but the market is still watching the company's performance closely.

Over the past few years, Biocon has been a strong performer in the pharmaceutical sector. The company's stock price has been volatile, with a high of ₹1,100 in early 2015 and a low of ₹750 in late 2015. The company's stock price has since recovered to its previous levels, but the market is still watching the company's performance closely.



The company's stock price has been volatile, with a high of ₹1,100 in early 2015 and a low of ₹750 in late 2015. The company's stock price has since recovered to its previous levels, but the market is still watching the company's performance closely.

The company's stock price has been volatile, with a high of ₹1,100 in early 2015 and a low of ₹750 in late 2015. The company's stock price has since recovered to its previous levels, but the market is still watching the company's performance closely.